CN Patent

CN121666239A — 用于通过静脉内推注施用的福奈妥匹坦

Assigned to Helsinn Healthcare SA · Expires 2026-03-13 · 0y expired

What this patent protects

通过静脉内推注，优选地在缩短的时间段内施用神经激肽‑1受体拮抗剂，优选地福奈妥匹坦的改善方法。

USPTO Abstract

通过静脉内推注，优选地在缩短的时间段内施用神经激肽‑1受体拮抗剂，优选地福奈妥匹坦的改善方法。

Drugs covered by this patent

fosnetupitant-chloride-hydrochloride (FOSNETUPITANT CHLORIDE HYDROCHLORIDE)

Patent Metadata

Patent number: CN121666239A
Jurisdiction: CN
Classification: —
Expires: 2026-03-13
Drug substance claim: No
Drug product claim: No
Assignee: Helsinn Healthcare SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.